|
|
|
|
Long-Term Outcomes Among Adult Survivors of Childhood Central Nervous System Malignancies in the Childhood Can
Journal of the National Cancer Institute Advance Access originally published online on June 17, 2009 2009 101(13):946-958; doi:10.1093/jnci/djp148 This Article Full Text Supplementary Data All Versions of this Article: 101/13/946 most recent...
Journal of the National Cancer Institute:
Jul 1 2009 11:10AM
Matching: central nervous system
|
Find similar documents
|
|
|
|
Transdermal Drug Delivery for CNS Conditions Expected to Exceed $1 Billion by 2012
While often overshadowed in the public consciousness by cancer and heart disease, recent trends in certain pathologies of the central nervous system are becoming equally challenging for clinicians and researchers.Growth in the...
|
|
|
INC Research, Inc. Bolsters CNS Team with Tom Zoda as Senior Vice President, Neuropsychiatry
' INC Research , Inc., a therapeutically-focused contract research organization (CRO) with a process for delivering reliable results, today announced the addition of Tom Zoda, PhD, as senior vice president of Neuropsychiatry to its esteemed ...
|
|
|
INC Research adds Tom Zoda to CNS team
INC Research Bolsters CNS Team with Tom Zoda as Senior Vice President, Neuropsychiatry PhD Brings Vast Clinical Expertise of Global CNS Trials Raleigh, NC, June 23, 2009 INC Research , Inc., a therapeutically-focused contract research...
|
|
|
Vets Who Repress Traumatic Memories May Not Be Worse Off
FRIDAY, June 19 (HealthDay News) -- Veterans suffering from (PTSD) may not be plagued by poor health and shortened lives if they repress their combat experiences, new research suggests.'The finding goes against the grain,' acknowledged...
|
|
|
Survivors Of Childhood Central Nervous System Cancer Face Persistent Risks As Adults
Long-term survivors of childhood central nervous system (CNS) malignancies remain at risk for death and are at increasing risk for developing subsequent cancers and chronic medical conditions over time, according to a new study....
|
|
|
Survivors Of Childhood Central Nervous System Cancer Face Persistent Risks As Adults
Long-term survivors of childhood central nervous system (CNS) malignancies remain at risk for death and are at increasing risk for developing subsequent cancers and chronic medical conditions over time, according to a new study...
|
|
|
Ipsen, Pharnext in exclusive R&D deal
French pharma company Ipsen and Pharnext SAS, a biopharmaceutical company have entered into an exclusive research, development and marketing agreement regarding innovative drug candidates intended for the treatment of Charcot Marie-Tooth...
|
|
|
Ipsen, Pharnext enter research, development & marketing agreement
Ipsen, an innovation-driven global pharmaceutical Group and Pharnext SAS, a biopharmaceutical company specializing in the development of innovative treatments, announced they have entered into an exclusive research, development and marketing...
|
|
|
Central Nervous System Disease Therapy: Researchers at AstraZeneca target central nervous system disease thera
Researchers at AstraZeneca target central nervous system disease therapy New investigation results, 'GABAB receptors as drug targets to treat gastroesophageal reflux disease,' are detailed in a study published in Pharmacology and...
|
|
|
Ipsen and PHARNEXT Conclude an Exclusive Research, Development and Marketing Agreement
A Press Conference Will Take Place This Morning at the FNSEA Amphitheatre From 8:45 to 11 am - 11 Rue de la Baume - 75008, Paris1 Ipsen (Paris:IPN) (Euronext : IPN), an innovation-driven global pharmaceutical Group and Pharnext SAS, a...
|
|
|
Ipsen and PHARNEXT Conclude an Exclusive Research, Development and Marketing Agreement
Regulatory News: Ipsen (Paris:IPN) (Euronext : IPN), an innovation-driven global pharmaceutical Group and Pharnext SAS, a biopharmaceutical company specializing in the development of innovative treatments, today announced they have entered...
|
|
|
Ipsen and PHARNEXT Conclude an Exclusive Research, Development and Marketing Agreement
Ipsen (Paris:IPN) (Euronext:IPN), an innovation-driven global pharmaceutical Group and Pharnext SAS, a biopharmaceutical company specializing in the development of innovative treatments, today announced they have entered into an exclusive...
|
|
|
Alder Biopharmaceuticals Announces Expanded Collaboration With Schering-Plough
Alder Biopharmaceuticals, Inc., an emerging antibody therapeutics company, today announced the expansion of its collaborative alliance with leading pharmaceutical company Schering-Plough Corporation (NYSE: SGP).The collaboration continues...
|
|
|
Groundbreaking Approach to Treating Obesity Highlighted by Keynote Lecture at American Diabetes Association An
Zafgen Scientific Advisory Board Member and Pioneering Researcher Dr.Randy J. Seeley Underscores the Active Role of Adipose Vasculature in Metabolic Disease CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 8, 2009 - Zafgen, Inc., a private...
|
|
|
Alder Biopharmaceuticals Announces Expanded Collaboration With Schering-Plough
News source: Business Wire Alder Biopharmaceuticals, Inc., an emerging antibody therapeutics company, today announced the expansion of its collaborative alliance with leading pharmaceutical company Schering-Plough Corporation (NYSE: SGP).
|
|
|
Alder Biopharmaceuticals Announces Expanded Collaboration With Schering-Plough
- Alder Biopharmaceuticals, Inc., an emerging antibody therapeutics company, today announced the expansion of its collaborative alliance with leading pharmaceutical company Schering-Plough Corporation (NYSE: SGP).The collaboration...
|
|
|
Groundbreaking Approach to Treating Obesity Highlighted by Keynote Lecture at American Diabetes Association An
News source: Business Wire Zafgen, Inc., a private venture-backed biopharmaceutical company focused on developing novel obesity therapeutics, today announced that Randy J.Seeley, Ph. D., professor of psychiatry and associate director...
|
|
|
Alder Biopharmaceuticals Announces Expanded Collaboration With Schering-Plough
Therapeutic Monoclonal Antibodies Generated From Antibody Identification & Production Technologies Selected as Lead Candidates BOTHELL, Wash.--(BUSINESS WIRE)--Jun 8, 2009 - Alder Biopharmaceuticals, Inc., an emerging antibody...
|
|
|
Alder Biopharmaceuticals Announces Expanded Collaboration With Schering-Plough
BusinessWire - Alder Biopharmaceuticals, Inc., an emerging antibody therapeutics company, today announced the expansion of its collaborative alliance with leading pharmaceutical company Schering-Plough Corporation (NYSE: SGP).The...
|
|
|
Alder Biopharmaceuticals Inc. Announces Expanded Collaboration With Schering-Plough Corporation (SGP) (JOBS)
BOTHELL, Wash.--(BUSINESS WIRE)--Alder Biopharmaceuticals, Inc., an emerging antibody therapeutics company, today announced the expansion of its collaborative alliance with leading pharmaceutical company Schering-Plough Corporation (NYSE:...
|
|
|
Alder Biopharmaceuticals Announces Expanded Collaboration With Schering-Plough
Alder Biopharmaceuticals, Inc., an emerging antibody therapeutics company, today announced the expansion of its collaborative alliance with leading pharmaceutical company Schering-Plough Corporation (NYSE: SGP).The collaboration continues...
|
|
|
Alder Biopharmaceuticals Announces Expanded Collaboration With Schering-Plough
Candidates with potential applications to Central Nervous System (CNS) disorders are being identified through the application of Alder's innovative high throughput antibody selection (ABS) system and yeast production ...
|
|
|
Alder Biopharmaceuticals Announces Expanded Collaboration With Schering-Plough
Alder Biopharmaceuticals, Inc., an emerging antibody therapeutics company, today announced the expansion of its collaborative alliance with leading pharmaceutical company Schering-Plough Corporation ( NYSE:SGP).The collaboration continues...
|
|
|
Alder Biopharmaceuticals Announces Expanded Collaboration With Schering-Plough
BOTHELL, Wash.--(BUSINESS WIRE)--Alder Biopharmaceuticals, Inc., an emerging antibody therapeutics company, today announced the expansion of its collaborative alliance with leading pharmaceutical company Schering-Plough Corporation (NYSE:...
|
